HCWB (HCW Biologics) 1-Year Sharpe Ratio: 0.37 (As of Jul. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HCWB HCW Biologics Inc HCWB
37 GF Score
Price $4.00
GF Value $43.75
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is HCW Biologics 1-Year Sharpe Ratio?

HCW Biologics HCWB -1.96% 37 1-Year Sharpe Ratio is 0.37 as of Jul. 19, 2026. GuruFocus rates HCWB with a GF Score™ of 37/100 and a GF Value™ of $43.75 (Possible Value Trap). The stock has 7 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-19), HCW Biologics's 1-Year Sharpe Ratio is 0.37.

HCW Biologics  (NAS:HCWB) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

HCW Biologics 1-Year Sharpe Ratio Related Terms

HCWB vs KAPA, IMNN, MTVA: 1-Year Sharpe Ratio Comparison

For the Biotechnology subindustry, HCW Biologics's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HCW Biologics 1-Year Sharpe Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HCW Biologics's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where HCW Biologics's 1-Year Sharpe Ratio falls into.


HCWB
37GF Score
HCW Biologics Inc HCWB
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

HCW Biologics 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of 0.37 mean?
HCW Biologics (HCWB) has a 1-Year Sharpe Ratio of 0.37 as of Jul. 19, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for HCW Biologics and its competitors.
Is HCW Biologics' 1-Year Sharpe Ratio too high?
HCW Biologics' current 1-Year Sharpe Ratio is 0.37. Overall, HCW Biologics has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' 1-Year Sharpe Ratio compare to KAPA and IMNN?
HCW Biologics' 1-Year Sharpe Ratio of 0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Biotechnology company?
A good 1-Year Sharpe Ratio depends on the Biotechnology industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for HCW Biologics and its competitors. HCW Biologics's current 1-Year Sharpe Ratio is 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $43.75, compared to a current price of $4.00 — trading 90.9% below its estimated fair value. The current 1-Year Sharpe Ratio is 0.37. HCW Biologics' overall GF Score™ is 37/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For HCW Biologics (HCWB), the current 1-Year Sharpe Ratio is 0.37 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HCW Biologics (HCWB) Overvalued in 2026?

Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued. The current stock price of $4.00 is trading 90.9% below its estimated GF Value™ of $43.75. GuruFocus considers HCW Biologics to be Possible Value Trap.

Key valuation signals for HCWB:

  • 1-Year Sharpe Ratio: 0.37
  • GF Value™: $43.75 vs. price of $4.00 (90.9% below fair value)
  • GF Score™: 37/100 with 7 warning signs

No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HCW Biologics Business Description

Address 2929 N. Commerce Parkway, Miramar, FL, USA, 33025
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
37GF Score

Get the complete analysis for HCWB

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.00
Price
$43.75
GF Value